Introduction {#Sec1}
============

The antigen D is the most important and immunogenic antigen of the Rh blood group \[[@CR1], [@CR2]\]. The proper identification of RhD antigen has a high clinical significance, and can play an important role in preventing the occurrence of hemolytic anemia in patients and newborns \[[@CR2]\]. Serology is the standard method for detection of RhD antigen, but has limitations. Genotyping by molecular techniques is a complementary tool to overcome these limitations. Some of the clinical applications of these methods are determination of *RHD* zygosity in RhD-positive fathers, assessment of RhD status in the fetus and multi-transfused patients, resolving the discrepancies in RhD typing in blood donors and patients with auto or alloantibodies \[[@CR3], [@CR4]\]. Knowing the prevalence of alleles responsible for the phenotype in a special population, and the establishment of appropriate molecular methods for detection of alleles are required for genotyping and its application in the clinic \[[@CR5]\]. Whereas in Caucasians deletion of the entire RHD gene is the most common cause of the RhD-negative phenotype, *RHDψ* (66%), *RHD*-*CE*-*D* hybrid gene (15%) and *RHD* gene deletion (18%) are the most prevalent causes of the RhD-negative phenotype among black Africans \[[@CR1], [@CR6]\]. Studies have shown that the D-negative phenotype is present in about 10.08% of the Iranian population \[[@CR7]\], but there are not any reports identifying the molecular background of D-negative phenotypes in our country. This study for the first time identified the genetic mechanisms of RhD-negative phenotype among the Iranian population. The hybrid *Rhesus box* is a genomic segment with an approximate length of 9000 base, resulting from the *RHD* gene deletion and the integration of two segments of upstream and downstream *Rhesus boxes* that flank the *RHD* gene. This hybrid sequence was used as a marker to identify the *RHD* gene deletion \[[@CR1]\]. Regarding the similarity of RhD-negative frequency among Caucasians and Iranian population and high prevalence of *RHD* gene deletion in Caucasians, we decided to evaluate the presence of hybrid *Rhesus box* genomic segment by PCR-SSP and PCR-RFLP. In addition, we performed real-time PCR to investigate the presence of *RHD* gene exons in our samples as a confirmatory test for gene deletion.

Materials and Methods {#Sec2}
=====================

Sample Collection {#Sec3}
-----------------

Blood samples obtained into K3EDTA-containing tubes from 200 RhD-negative randomly selected donors at the Tehran Blood Transfusion Center. This study was approved by the Ethics Committee of the Institute for Educational and Research in Transfusion Medicine.

Phenotype Determination {#Sec4}
-----------------------

The antigenic phenotype (D, C, E, c, e) of red blood cells were determined for all specimens using a monoclonal antibody (IMMUNDIAGNOSTIKA, GmbH, Germany) by standard serological method. Monoclonal antibody reagents were used to test the following specificities: anti-C (RH2, clone MS24), anti-E (RH3, clone MS80/MS258), anti-c (RH4, clone MS33) and anti-e (RH5, clone MS62/MS69).The anti-D reagent was a blend of both IgG and IgM. Subsequently, weak D test was performed on all samples by indirect antiglobulin test (IAT) according to the standard serological guidelines. Adsorption--elution test was not performed in this study.

DNA Extraction {#Sec5}
--------------

Genomic DNA was extracted from buffy coat samples using column-based DNA extraction kit (YT 9040, YEKTA TAJHIZ AZMA, IRAN). The extracted DNA was stored at − 20 °C after determining the concentration using the *Nano Drop* (one/one^c^, Thermo Fisher Scientific Inc, USA).

PCR-SSP {#Sec6}
-------

A 2778-bp fragment was amplified from the hybrid *Rhesus box* gene, causing by deletion the *RHD* gene. This segment flanking the breakpoint region in the hybrid *Rhesus box* gene comprised of segments from upstream *Rhesus box* (775 bp), identity region (1467 bp) and downstream *Rhesus box* (536 bp) \[[@CR1]\]. The segment was amplified by the forward primer (u1-s) and reverse primer (rnb31) (Table [1](#Tab1){ref-type="table"}). PCR reaction was performed in a volume of 25 μl in 35 cycles using thermal cycler (PEQSTAR 2X 95-08002, PEQLAB Biotechnology GmbH, Germany) under the following conditions: initial denaturation at 95 °C for 10 min, denaturation at 92 °C for 20 s, annealing at 64 °C for 30 s, extension at 68 °C for 3 min, final extension at 72 °C for 5 min. The concentration of forward and reverse primers was 0.4 μm. The PCR products were electrophoresed on 0.8% agarose gel.Table 1Sequence and specificity of primers comprising segments of hybrid (AJ252313), downstream (AJ252312) and upstream *Rhesus box* (AJ252311)(Reproduced with permission from \[[@CR1], [@CR8], [@CR9]\])PrimerSequenceSpecificityu1-sTGAGCCTATAAAATCCAAAGCAAGTTAGHybrid and upstream *Rhesus box*rnb31CCTTTTTTTGTTTGTTTTTGGCGGTGCHybrid and downstream *Rhesus box*rez7CCTGTCCCCATGATTCAGTTACCHybrid and downstream and upstream *Rhesus box*

PCR-RFLP {#Sec7}
--------

The PCR-RFLP was used to discriminate the status of homo- or heterozygosity of *RHD* gene deletion allele \[[@CR1]\]. The primers were designed so that they could amplify both fragments of the hybrid *Rhesus box* in the deletion of *RHD* gene and also of the downstream *Rhesus box* in the presence of *RHD* gene \[[@CR1], [@CR8], [@CR9]\]. The sequences of forward (Rez7) and reverse (rnb31) primers are shown in Table [1](#Tab1){ref-type="table"}. PCR reaction was performed as described for PCR-SSP, but the number of cycles was 30 and annealing temperature was 68 °C. The PCR products were digested with *Pst*I enzyme (Jena Bioscience, GmbH, Germany) for 1 h at 37 °C and electrophoresed on 2% agarose gel.

Real-time PCR {#Sec8}
-------------

The real-time PCR was used to investigate the presence of three exons 5, 7 and 10 in the *RHD* gene by sequence-specific primers (Table [2](#Tab2){ref-type="table"}). The RHD-positive sample was used as a control for the amplification of exons and melting curve analysis of PCR products. In the presence of *RHD* gene deletion, none of the three exons would be amplified, while in the presence of any *RHD* allele that resulted in RhD-negative phenotype it was expected that one or more of these exons would be amplified based on the type of the allele \[[@CR10], [@CR11]\].Table 2Primers' sequence of exons 5, 7, and 10 of the *RHD* gene(Reproduced with permission from \[[@CR12]\])GeneForward/reverseSequenceProduct sizeExon 5F5′-CGCCCTCTTCTTGTGGATG-3′82 bpR5′-GAACACGGCATTCTTCCTTTC-3′Exon 7F5′-CTCCATCATGGGCTACAA-3′90 bpR5′-CCGGCTCCGACGGTATC-3′Exon 10F5′-CCTCTCACTGTTGCCTGCATT-3′74 bpR5′-AGTGCCTGCGCGAACATT-3′

Real-time PCR reaction was performed in a volume of 25 μl in 30 cycles using thermal cycler (Rotor-Gene, RG3000, Corbett, Australia) and SYBR Green Master Mix under the following conditions: initial denaturation at 94 °C for 2 min, denaturation at 95 °C for 30 s, annealing at 55 °C for 30 s, extension at 72 °C for 30 s. The concentration of forward and reverse primers for each exon was 0.4 μm.

*RHD*-*CE*-*D* Hybrid Molecular Analysis {#Sec9}
----------------------------------------

We initially analyzed the presence of exons 3, 4, 6 and 9 of *RHD* gene using the PCR-SSP method \[[@CR13]\] in one sample whose real-time PCR reaction was positive for exon 10. Then, we investigated the presence of introns 1 and 2 of the *RHD* gene by PCR-RFLP \[[@CR14], [@CR15]\].

Weak D Molecular Analysis {#Sec10}
-------------------------

Weak D molecular diagnostic kit (inno-train, Diagnostic GmbH, Germany) was used for further analysis of the positive sample in which the three exons 5, 7 and 10 were amplified by RT-PCR according to the manufacturer's guidelines. Exon 6 was sequenced (ABI 3130 XL Applied Biosystem, Macrogene, Korea) to confirm the weak D allele type.

Results {#Sec11}
=======

Rh Antigen Phenotypes {#Sec12}
---------------------

The phenotype of the antigens D, C, E, c, e was determined on samples of 200 blood donors (Table [3](#Tab3){ref-type="table"}). An indirect antiglobulin test was performed for the elimination of donors with weak D phenotype. The result of indirect antiglobulin test proved negative in all donors.Table 3Frequency of phenotypes and predicted genotypesPhenotypesThe most probable genotypesNumber(200 samples)Frequency (%)D−C−E−c+e+cde/cde18492D−C+E−c−e+Cde/Cde42D−C+E−c+e+Cde/cde115.5D−C−E+c+e+cdE/cde10.5

Hybrid *Rhesus box* Gene Analysis by PCR-SSP {#Sec13}
--------------------------------------------

The genomic segment with a length of 2778 bp was amplified using PCR-SSP technique, indicating that all 200 (100%) donors were positive for hybrid *Rhesus box* gene in at least one allele (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1PCR-SSP for hybrid *Rhesus box* gene. A 2778 bp fragment was amplified by PCR-SSP indicates the presence of hybrid *Rhesus box* gene (lanes 1--10). Lane 11: Negative control. M: Molecular marker 1 kb (YT8507, YEKTA TAJHIZ AZMA, IRAN)

Zygosity Analysis of Hybrid *Rhesus box* Gene by PCR-RFLP {#Sec14}
---------------------------------------------------------

A genomic segment with an approximate length of 3030 bp was amplified by PCR and specific primers and digested with *Pst*I enzyme. The number and size of fragments on a 2% agarose gel showed that 198 (99%) of donors had a hybrid *Rhesus box* genomic segment in both RH gene alleles (homozygote) (Fig. [2](#Fig2){ref-type="fig"}a) and the 2 remaining donors (1%) had a hybrid *Rhesus box* in one of the RH gene alleles (heterozygote); in the latter, in addition to hybrid *Rhesus box,* a genomic segment was amplified from downstream *Rhesus box* of another allele (Fig. [2](#Fig2){ref-type="fig"}b).Fig. 2PCR-RFLP analysis for RHD gene deletion. **a** Banding patterns of RHD−/RHD− homozygotes. There are 3 *Pst*I sites in the hybrid *Rhesus box* amplicons. Digestion with this enzyme (*Pst*I) results in 179, 397, 564, 1887-bp fragments (lanes 1--9). **b** PCR-RFLP for RHD+/RHD− heterozygous samples. An additional 744-bp fragment results from downstream *Rhesus box* digestion and indicates the heterozygous situation (lanes 1--2). M: Molecular marker 100 bp (YT8503, YEKTA TAJHIZ AZMA, IRAN)

*RHD* Exons Analysis {#Sec15}
--------------------

In this study, none of the exons 5, 7 and 10 were amplified in 198 (99%) of 200 samples studied by real-time PCR. Of the two remaining samples (1%), all three exons 5, 7 and 10 were amplified in one sample, and in the other one only exon 10 was amplified. In the positive sample for all three exons 5, 7 and 10 with more molecular analysis by the diagnostic kit, weak D allele type 11 (885 G\>T) was detected and confirmed by sequencing of exon 6. In the sample that was positive only for exon 10, the results of PCR-SSP for exons 3, 4, 6 and 9 indicated that these exons were absent in the *RHD* gene in this case. Results of molecular analysis of introns 1 and 2 showed that this sample is a *RHD*-*CE (2*-*9)*-*D*~*2*~ hybrid allele. (Table [4](#Tab4){ref-type="table"}).Table 4Frequency of *RHD* gene alleles in RhD-negative samplesRHD gene allelesNumber\
(200 samples)(%)PhenotypesPCR-SSP (for hybrid *Rhesus box*)PCR-RFLP\
(for *RHD* gene deletion)*RHD* exons 5, 7, 10Gene deletion19899D−C−E−c+e+ (92.92%)\
D−C−E+c+e+ (0.5%)\
D−C+E−c−e+ (1.51%)\
D−C+E−c+e+ (5.05%)+Homozygote--Weak D type 1110.5D−C+E−c−e++Heterozygote+*RHD*-*CE(2*-*9)*-*D*~*2*~10.5D−C+E−c+e++HeterozygoteOnly 10 +

Discussion {#Sec16}
==========

The prevalence of D-negative phenotype is estimated to be between 15 and 17% among Caucasians, 5% in black Africans and less than 3% in Asians \[[@CR16]\]. The prevalence of D-negative phenotype in Iran is estimated at approximately 10.08% \[[@CR7]\], which is more consistent with the Caucasian population. This study for the first time identified the genetic mechanisms of D-negative phenotype among the Iranian population.

Our results, using the PCR-SSP, showed that all donors were positive for the presence of a 2778 bp genomic segment obtained from the hybrid *Rhesus box* gene. The amplification of this segment implies that all donors have at least one *RHD* gene deletion allele, and another allele of the *RHD* gene may be a deletion or non-deletion allele. Therefore, the PCR-RFLP was used to check the status of the other allele for the presence or absence of *RHD* gene.

The results of PCR-RFLP showed that 198 (99%) of donors in both RH gene alleles had a hybrid *Rhesus box* genomic segment, which means that these cases are homozygote for *RHD* gene deletion. Analysis of exons 5, 7 and 10 using real-time PCR also showed that none of the three exons were amplified in these 198 donors, and the PCR-SSP and PCR-RFLP results were confirmed. Moreover, the PCR-RFLP results showed that 2 (1%) of the RhD-negative donors had a *RHD* gene allele. The analysis of exons 5, 7 and 10 using real-time PCR showed that all three exons 5, 7 and 10 were amplified in one sample, but, in the other one, only exon 10 was amplified. In the first sample, further molecular analysis showed that the donor had a weak D allele type 11 that has not been detected by the weak D serological test. In some cases, the weak D phenotype may not be detected by the conventional serological tests (indirect anti-globulin test) \[[@CR17]\]. The 885 G\>T mutation associated with the replacement of M295I results in lowered density of D antigen on red blood cells in the weak D type 11 \[[@CR18]\]. In the second sample that was positive only for exon 10, the results of further molecular analyses for exons 3, 4, 6 and 9 and introns 1 and 2 of *RHD* gene indicated the presence of the *RHD*-*CE (2*-*9)*-*D*~*2*~ hybrid allele. Several studies in East Asia have shown that the most common mechanisms for the D-negative phenotype in this population are the *RHD* gene deletion, the DEL allele (approximately 10--30%) and the *RHD*-*CE*-*D* hybrid allele (approximately 10%) \[[@CR19], [@CR20]\]. These genetic backgrounds of RhD-negative are different from the Iranian population located in the Middle East, while the frequency of our results is more similar to the European population \[[@CR21]\]. The frequency of D-negative phenotype with a non-deletion *RHD* gene allele is approximately 0.6% in Caucasians, 10% in black Africans and 30% in Asians \[[@CR2], [@CR22]\]. In our study, non-deletion *RHD* gene allele was found in 2 (1%) D-negative donors, indicating more consistency with the Caucasian population. Genotyping of RhD-negative donors at the blood transfusion centers is very important because some alleles like DEL and weak D may not be detected by conventional serological tests and are considered as RhD-negative. Transfusion of these blood products into RhD-negative individuals, especially for girls and women with childbearing potential, may increase the risk of immunization with anti-D in these individuals. So, the screening of RhD-negative donors by genotyping for identification of *RHD* gene alleles, especially in a population where these alleles are highly prevalent, can be very important \[[@CR17], [@CR23]\]. Despite the high prevalence of DEL allele in East Asia (approximately 10--30% of the RhD-negative population), our results (high frequency of *RHD* gene deletion) imply that the frequency of the DEL allele among the Iranian population should be very low and similar to the Caucasian population \[[@CR21], [@CR24]\]. In our study, the *RHD* gene deletion had the highest association with the D−C−E−c+e+ phenotype (92.92%) and 87.5% of the C+/E+ donors had *RHD* gene deletion alleles. The frequency of D-negative phenotype with the presence of *RHD* gene non-deletion alleles in association with C and E antigens has also been reported \[[@CR2], [@CR11]\]. Both donors with non-deletion allele in this study were positive for C antigen.

Conclusion {#Sec17}
==========

In this study, using PCR-SSP, PCR-RFLP, and real-time PCR to identify the genetic background of D-negative phenotype showed that *RHD* gene deletion is the most common genetic mechanism for D-negative phenotype in Iran. The results of the present study are consistent with other studies performed in Caucasians. Furthermore, hybrid *Rhesus box* molecular analysis could effectively identify this allele.
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